Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

ISCHEMIC CARDIOMYOPATHY Clinical Trial

Official title:

Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02933034
• Other study ID #: 28508
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: April 2015
• Est. completion date: February 3, 2019

Study information

• Verified date: February 2020
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerance of a new intravenous diagnostic agent, SeeMore or EVP 1001-1, in patients with Cardiovascular Disease (MEMRI scan). The initial phase of this study, NCT01989195 enrolling a total of 6 patients, has been closed. This second phase adds 10 patients in a safety cohort and 60 additional patients for a total of 70 patients.

Description:

This is an open-label, baseline-controlled study to be conducted. Adult male or nonpregnant female patients who have been referred for evaluation of dilated cardiomyopathy, ischemic cardiomyopathy, non-ischemic cardiomyopathy, atrial arrhythmia and also patients who have received stem cell therapy related to both ischemic and dilated cardiomyopathy (under different trials) will be recruited. An initial cohort study of 6 patients to conduct safety evaluation was conducted before proceeding with 60 additional patients. In the initial cohort, a patient was dosed based on the Phase 1 and 2 clinical trial data evaluation completed by Eagle Vision Pharmaceutical, Inc. Subjects were excluded if they had received an investigational device within 30 days prior to administration of EVP1001-1; had a history of drug abuse or alcoholism; were taking a digitalis preparation; had a history of torsades; had New York Heart Association (NYHA) Grade IV heart failure; had abnormal liver function tests or a history of liver disease; had uncontrolled hypertension; had abnormal calcium, potassium or hemoglobin values at baseline; if they develop a cardiac arrhythmia prior to or during either of the exercise tests-- EVP1001-1 was not administered. The same parameters will apply to the new group of subjects.

Prior to entry into this study, all subjects will sign an Informed Consent and will undergo a physical examination including medical history, details regarding their cardiac history, prescription and over-the-counter drug questionnaire, vital signs, electrocardiogram (ECG), evaluation of the major organ systems, hematology, serum chemistries, and urinalysis. In addition, female subjects will undergo a serum pregnancy test.

Starting 30 minutes before the cardiac MRI scan (CMR), the subjects will take a 16 mg tablet of ondansetron by mouth. CMR imaging will subsequently take place and then EVP1001-1 will then be administered approximately 15 minutes into the scan for contrast enhanced images. EVP1001-1 will be administered intravenously over approximately one minute. The subjects will each receive 0.28 mL/kg of EVP 1001-1. All subjects will be monitored closely from before ondansetron administration until their discharge from the imaging center. Following MEMRI, delayed-enhanced MRI (DEMRI scan) is performed using 0.2 mmol/kg.

We will compare the two different contrast enhanced images (EVP1001-1 vs gadolinium (GD)) in determining the non-viable (infarct core), peri-infarct, and total infarct size of myocardial tissue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: February 3, 2019
• Est. primary completion date: February 3, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

All subjects to be entered must:

• be at least 18 years of age.

• if female, be nonpregnant as evidenced by a serum pregnancy test and using a medically-approved method of birth control, or post-menopausal or surgically sterile

• provide written informed consent after having received oral and written information about the study

• be in stable health based on medical history, examination and tests

Exclusion Criteria:

have a positive pregnancy test (females)

• received an investigational drug or device within 30 days prior to administration of SeeMore

• have known hypersensitivity to ondansetron or other selective serotonin 5HT3 receptor blockers

• have a history of drug abuse or alcoholism

• are taking a digitalis preparation or calcium channel blocker

• have a history of torsades or prolonged QT/QTc interval

• have NYHA Grade IV heart failure

• have abnormal liver function tests or a history of liver disease

• have uncontrolled hypertension (Systolic Blood Pressure > 140 or Diastolic BP > 90 consistently at baseline)

• have abnormal baseline potassium or calcium values or hemoglobin less than 10 g/dl

• are noncompliant or otherwise unlikely to perform as required by the protocol

• have pretest likelihood of CAD for which the requisite number of subjects have been entered

• develop an arrhythmia prior to or during either of the exercise tests; SeeMore should not be administered.

Related Conditions & MeSH terms

• Cardiomyopathies
• Infarction
• ISCHEMIC CARDIOMYOPATHY

Intervention

Drug:
• Manganese-enhanced MRI contrast reagent
MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
• Gadolinium-enhanced MRI contrast reagent
MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	General Electric

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Infarct Size of MEMRI Versus DEMRI Scans	MEMRI is an assessment of non-viable myocardial tissue and evaluates core infarct size. DEMRI is an assessment of fibrotic tissue and evaluates the total infarct size. The difference between these two measurements evaluates the size of peri-infarct region consisting of mixed components of injured but viable cardiomyocytes and fibrosis.	Day of MEMRI and DEMRI scans (up to 3 hours per scan, performed on the same day or up to 7 days apart)
Secondary	Systolic Blood Pressure	Systolic blood pressure during MEMRI scan as a measure of manganese contrast reagent safety. Normal reference range: 90-120 mmHg.	Before, during, and after MEMRI scan (up to 3 hours)
Secondary	Diastolic Blood Pressure	Diastolic blood pressure during MEMRI scan as a measure of manganese contrast reagent safety. Normal reference range: 60-80 mmHg.	Before,during, and after MEMRI scan (up to 3 hours)
Secondary	Heart Rate	Heart rate during MEMRI scan as a measure of manganese contrast reagent safety. Normal reference range: 60 and 100 beats per minute.	Before,during, and after MEMRI scan (up to 3 hours)
Secondary	QT Interval	QT interval during MEMRI scan as a measure of manganese contrast reagent safety. QT is a measurement of heart function that is dependent on heart rate, so QTc is mainly used for diagnosis rather than QT. Normal reference range was considered to be 360-450 milliseconds for this study.	Before and after MEMRI scan (up to 3 hours)
Secondary	Corrected QT (QTc)	Corrected QT (QTc) interval during MEMRI scan as a measure of manganese contrast reagent safety. QTc is a measurement of heart function and is mainly used for diagnosis rather than QT, because QT is dependent on heart rate. Normal reference range was considered to be 360-450 milliseconds for this study.	Before and after MEMRI scan (up to 3 hours)
Secondary	Alanine Aminotransferase (ALT)	ALT levels during MEMRI scan as a measure of manganese contrast reagent safety. ALT is a measurement of liver function. Normal reference range was considered to be <60 U/L for this study.	Before and after MEMRI scan (up to 3 hours)
Secondary	Aspartate Aminotransferase (AST)	AST levels during MEMRI scan as a measure of manganese contrast reagent safety. AST is a measurement of liver function. Normal reference range was considered to be <40 U/L for this study.	Before and after MEMRI scan (up to 3 hours)
Secondary	Alkaline Phosphatase (ALP)	ALP levels during MEMRI scan as a measure of manganese contrast reagent safety. ALP is a measurement of liver function. Normal reference range was considered to be <40-130 U/L for this study.	Before and after MEMRI scan (up to 3 hours)
Secondary	Total Bilirubin	Total bilirubin levels during MEMRI scan as a measure of manganese contrast reagent safety. Total bilirubin is a measurement of liver function. Normal reference range was considered to be <1.4 mg/dL for this study.	Before and after MEMRI scan (up to 3 hours)
Secondary	Creatinine	Creatinine levels during MEMRI scan as a measure of manganese contrast reagent safety. Creatinine is a measurement of kidney function. Normal reference range was considered to be 0.50-1.20 mg/dL for this study.	Before and after MEMRI scan (up to 3 hours)
Secondary	Estimated Glomerular Filtration Rate (eGFR)	eGFR levels during MEMRI scan as a measure of manganese contrast reagent safety. eGFR is a measurement of kidney function. Normal reference range was considered to be >60 ml/min/1.73m^2 for this study.	Before and after MEMRI scan (up to 3 hours)